April 24, 2025

Old Drug, New Trick for Joint Pain

Can a common diabetes drug double as a treatment for knee osteoarthritis?

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 21, 2025

Higher Dietary Acid Load Tied to Knee OA

“This study demonstrates a significant association between high DAL and increased odds of [knee] OA.”

Conexiant

April 21, 2025

Lupus Clusters Show Distinct Disease Patterns

Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.

Conexiant

April 21, 2025

Key Risk Factors for Shoulder Pain

"Three of the five significant risk factors for injury can be identified by objective pre-screening measures."

Conexiant

April 16, 2025

Is Primary Care Becoming Pay-to-Play?

“It’s a way to practice self-preservation in this field that is punishing patients and doctors alike” — one internist explains why some rural physicians are opting for concierge care despite the access trade-offs.

KFF Health News

April 16, 2025

How Do Feet Beat the Stress?

"As the calcaneus grows in size, it becomes taller, wider, and relatively shorter—essentially, more cube-like—revealing nature’s quiet strategy to manage internal bone stress."

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant